Partner and Co-Founder
New York Office | tim.opler@torreya.com | 212.257.5802
Tim Opler, Partner and Co-Founder of Torreya, manages client relationships and oversees the firm’s administrative activities.
Tim has 24 years experience leading strategic and financing transactions across multiple sectors. For nearly 20 years, he has focused exclusively on life sciences advisory; he has completed more than 150 financing, licensing, and M&A transactions across the industry with a total value of over $100 billion. Highlights include running the largest share buyback in history for Pfizer, leading a $3.9 billion convertible bond exchange for Amgen, working on Chiron’s $5.1 billion sale to Novartis, and managing Genentech’s inaugural $2 billion bond issue.
Before co-founding Torreya, Tim was Vice President of Strategy at FibroGen, where he helped raise $117 million for the company and negotiated licensing deals. Previously, Tim was a Managing Director in Healthcare Investment Banking at Credit Suisse First Boston and held senior roles at W.R. Hambrecht, Deutsche Bank, and Merrill Lynch.
Other notable transactions on which Tim advised prior to starting Torreya include advising Pfizer on the sales of Heumann, Dorom, and NM Pharma; managing $1.1 billion in swaps and bond issues for Eli Lilly; managing $150 million in derivatives for Guidant; managing $850 million in bond issuance and swaps for Bristol-Myers Squibb; acting as a lead on Glaxo’s $1 billion bond issue; and leading a $600 million Eurobond issue for Pfizer. He has also led transactions and served as a strategic advisor for BHP, BMW, BP, Coca-Cola Enterprises, Daimler, Dell, Diageo, Dow, Ford, GE, GM, the State of Israel, Microsoft, Philip Morris, the State of Poland, and Royal Dutch Shell, among others.
Prior to his career in investment banking, Tim was a professor in the finance department at Ohio State University. He earned a B.S. in economics and philosophy from Florida State University, and a Ph.D. in economics from UCLA.
![]() |
Advisor to the Special Committee of the Board of Directors in its merger with |
![]() |
$1.5 billion
October 2020
|
|
Acquisition of |
![]() |
$225 million
September 2020
|
![]() |
License of NOV03 in North America to |
![]() |
December 2019
|
![]() |
Debt recapitalization and acquisition of NextWave Pharmaceuticals from |
![]() |
$125 million
September 2018
|
![]() |
Acquisition of generics business of |
![]() |
$1.05 billion
June 2017
|
![]() |
Divestment of Leiden, Netherlands facility to |
![]() |
December 2022
|
![]() |
Recommended cash acquisition by |
![]() |
£48.3 million
November 2022
|
![]() |
Advisor on direct public offering |
![]() |
September 2022
|
![]() |
In-licensing of global rights to AVTX-007 from |
![]() |
Up to $89 million
August 2022
|
![]() |
Sale to |
![]() |
$73 million
May 2022
|
![]() |
Licensing of LM-302 to |
![]() |
Up to $1.2 billion in milestones + royalties ($25 million upfront)
May 2022
|
![]() |
Sale to |
![]() |
June 2021
|
![]() |
R&D collaboration agreement with |
![]() |
February 2021
|
![]() |
Exclusive license agreement to commercialize Triferic® in South Korea with |
![]() |
September 2020
|
![]() |
Sale of Noden to |
![]() |
Up to $52.83 Million
September 2020
|
![]() |
Co-advisor on direct public offering |
![]() |
$15 million
August 2020
|
![]() |
License of Vicineum™ in Greater China Region to |
![]() |
$12 million upfront
July 2020
|
![]() |
Disposal of stake in |
![]() |
$68 million
May 2020
|
![]() |
Strategic investment from |
![]() |
$30 million
February 2020
|
![]() |
Majority recap by |
![]() |
$125 million
April 2019
|
![]() |
Venture debt raise with |
![]() |
$20 million
April 2019
|
![]() |
Financing with |
![]() |
$40 Million
March 2019
|
![]() |
JV Partnership in China with |
![]() |
$50 million
December 2018
|
![]() |
License of Durasert™ in Ophthalmology in the Greater China Region to |
![]() |
Up to $11.75 million
November 2018
|
![]() |
Acquires royalty interest position for 7 assets from |
![]() |
$15 million
September 2018
|
![]() |
Partial royalty monetization with |
![]() |
$7.5 Million
June 2018
|
![]() |
License and collaboration agreement for global rights for LPA receptor program with |
![]() |
Up to $200 million
May 2018
|
![]() |
Debt financing for acquisition of Icon Biosciences from |
![]() |
$20 Million
March 2018
|
![]() |
Merger with |
![]() |
$34.9 million
November 2017
|
![]() |
License of Gevokizumab and certain associated IP to |
![]() |
$31 million upfront
August 2017
|
![]() |
Sale of generics portfolio to |
![]() |
$18 million
August 2017
|
![]() |
Company sale to |
![]() |
June 2017
|
![]() |
Sale of US dermatology business to |
![]() |
$13.6 million
May 2017
|
![]() |
Company sale to |
![]() |
$35.9 million
March 2017
|
![]() |
Microbiome partnership with |
![]() |
$2.6 billion
($50 million upfront) January 2017
|
![]() |
Sale of royalties to |
![]() |
$22 million
December 2016
|
![]() |
Merger with |
![]() |
$251 million
December 2016
|
![]() |
Collaboration agreement for Emricasan with |
![]() |
$50 million upfront
December 2016
|
![]() |
Has merged with Aspen Park Pharma to form |
![]() |
November 2016
|
![]() |
Partial sale of royalty and milestones |
![]() |
$40 million
September 2016
|
![]() |
Partial royalty and milestone sale to |
![]() |
$6 million
August 2016
|
![]() |
Licensing of Dalbavancin from |
![]() |
$13 million upfront
May 2016
|
![]() |
Preferred equity investment |
![]() |
$7 million
January 2016
|
![]() |
Sale of biologics manufacturing facilities to |
![]() |
$5 million in cash +
$1 million in stock November 2015
|
![]() |
License of global rights for Anti-TGF-beta antibody program to |
![]() |
Up to $517 million
October 2015
|
![]() |
Sale of FXR program to |
![]() |
Up to $470 million
January 2015
|
![]() |
Sale of Pessac plant to |
![]() |
Up to €22 million
November 2014
|
![]() |
Acquisition of |
![]() |
Up to $35 million
October 2014
|
![]() |
Global offering advisory |
![]() |
$133 million
October 2014
|
![]() |
Synthetic royalty financing from |
![]() |
$10 million
October 2014
|
![]() |
Sale to |
![]() |
$65 million
September 2014
|
![]() |
Merger with |
![]() |
$24 million
July 2014
|
![]() |
Sale to |
![]() |
$658 million
June 2014
|
![]() |
Sale to |
![]() |
$75 million upfront + milestones
May 2014
|
![]() |
Financial advisor on follow-on offering |
![]() |
$72.5 million
February 2014
|
![]() |
Sale to |
![]() |
December 2013
|
![]() |
Sale to |
![]() |
19.9% of shares +
$12 million November 2013
|
![]() |
Financial advisor in private placement |
![]() |
€29.9 million
November 2013
|
![]() |
Advisor on oncology partnership with |
![]() |
$550 million with
$10 million upfront August 2013
|
![]() |
Sale of vaccine company to |
![]() |
$250 million with
$35 million upfront May 2013
|
![]() |
Divestiture of three pediatric drugs to |
![]() |
$28.7 million
May 2013
|
![]() |
Sale of basket of royalties to |
![]() |
$6 million upfront
April 2013
|
![]() |
Acquisition of EU rights to Vibativ® from |
![]() |
$5 million + royalties
March 2013
|
![]() |
Sale for up to $106 million to |
![]() |
$12 million +
milestones January 2013
|
![]() |
Collaboration with |
![]() |
December 2012
|
![]() |
Sale of Fareston® to |
![]() |
$21.7 million
October 2012
|
![]() |
Sale of Amicar® rights to |
![]() |
August 2012
|
![]() |
Divestiture of Cuvposa® to |
![]() |
August 2012
|
![]() |
Sale of Roxicodone® to |
![]() |
August 2012
|
![]() |
Sale of Zipsor® to |
![]() |
June 2012
|
![]() |
Structured debt transaction linked to three pharma royalties |
![]() |
$65 million
December 2011
|
![]() |
Sale to |
![]() |
$10 million +
milestones October 2011
|
![]() |
Financial advisor in follow-on financing for GI company |
![]() |
July 2011
|
![]() |
Sale of Canadian biotechnology company to |
![]() |
May 2011
|
![]() |
Co-promotion for Zipsor® |
![]() |
May 2011
|
![]() |
Sale of royalties for Cubicin® and Lexiscan® to |
![]() |
$487 million
April 2011
|
![]() |
Advisor in iSonep license to |
![]() |
$500 million with
$14 million upfront December 2010
|
![]() |
Sale of dermatology specialty pharma business to |
![]() |
December 2010
|
![]() |
Sale to |
![]() |
$100+ million
October 2010
|
![]() |
Advisor in the acquisition of six products from |
![]() |
July 2010
|
![]() |
Sale of Crinone® & Prochieve® product lines and shares to |
![]() |
$92.5 million with
$47 million upfront July 2010
|
![]() |
Acquisition of |
![]() |
$40 million +
milestones June 2010
|
![]() |
Advisor to Genentech major shareholder in sale to |
![]() |
$46 billion
March 2009
|
![]() |
Sale to |
![]() |
September 2008
|
![]() |
Sale to |
![]() |
April 2008
|